transcatheter aortic valve replacement

ACC 2021 | ATLANTIS: Apixaban post TAVI vs tratamiento estándar

ACC 2021 | ATLANTIS 4D-CT: Apixaban and Sub-Clinical Thrombosis After TAVR

Indicating apixaban after transcatheter aortic valve replacement (TAVR) does not significantly reduce the risk of sub-clinical leaflet thrombosis compared with the standard of care. These data come from the computerized tomography (CT) scan sub-study from ATLANTIS, presented during the scientific sessions of the American College of Cardiology (ACC) 2021 Congress. In patients with no prior<a href="https://solaci.org/en/2021/05/19/acc-2021-atlantis-4d-ct-apixaban-and-sub-clinical-thrombosis-after-tavr/" title="Read more" >...</a>

ACC 2021 | ATLANTIS: Apixaban post TAVI vs tratamiento estándar

ACC 2021 | ATLANTIS: Apixaban After TAVR vs. Standard of Care

Adding apixaban to the treatment of patients undergoing transcatheter aortic valve replacement (TAVR) was non-superior to standard antithrombotic treatment, according to the randomized ATLANTIS trial presented today at the American College of Cardiology (ACC) 2021 Congress. Given its easy indication and good safety profile, it could be an option to vitamin&nbsp;K antagonists for patients with<a href="https://solaci.org/en/2021/05/18/acc-2021-atlantis-apixaban-after-tavr-vs-standard-of-care/" title="Read more" >...</a>

The Most Read Articles of August in Interventional Cardiology

01- Myocardial Injury for COVID-19 Even in Young Patients with Mild Symptoms Most young COVID-19 patients not requiring hospitalization showed abnormal cardiac magnetic resonance imaging (CMR) beyond two months after diagnosis. Read more HERE 02- Rapid Drop of Antibodies in Mild COVID-19 patients A fast drop in COVID-19 antibodies in mild patients triggers the alarm<a href="https://solaci.org/en/2020/09/03/the-most-read-articles-of-august-in-interventional-cardiology/" title="Read more" >...</a>

EuroPCR 2020 | A Trick to Find the Perfect Projection to Treat Ostia or Bifurcation Lesions

The trick is to avoid testing empirically more to the right or to the left, a more caudal or cranial angular, and check what a multislice computed tomography suggests. The increase in coronary computed tomography imaging studies—due to guideline recommendations, practicality, and patient comfort—means that we frequently have these data in the cath lab even<a href="https://solaci.org/en/2020/07/14/europcr-2020-a-trick-to-find-the-perfect-projection-to-treat-ostia-or-bifurcation-lesions/" title="Read more" >...</a>

TAVI SURAVI

SURTAVI Follow-Up Completed with Good News

The assessment of all severe aortic stenosis patients at intermediate risk of the SURTAVI was finally completed, confirming inferiority against the traditional surgical replacement (SAVR) in hard points such as all-cause mortality and disabling stroke.&nbsp; The aim of this study was to report SURTAVI 2-year outcomes (Surgical Replacement and Transcatheter Aortic Valve Implantation) and confirm<a href="https://solaci.org/en/2020/04/29/surtavi-follow-up-completed-with-good-news/" title="Read more" >...</a>

AHA 2019 | GALILEO-4D: rivaroxabán y prevención de engrosamiento y trombosis de las valvas post TAVI

AHA 2019 | GALILEO: Rivaroxaban After TAVI, Another Nice Theory that Clashes with Reality

In patients without formal indication for oral anticoagulation after successful transcatheter aortic valve implantation (TAVI), a treatment strategy including rivaroxaban 10 mg daily was associated with a higher risk of death or thromboembolic complications and, on top of that, a higher risk of bleeding than a conventional antiplatelet strategy. So far, we did not know whether<a href="https://solaci.org/en/2019/11/21/aha-2019-galileo-rivaroxaban-after-tavi-another-nice-theory-that-clashes-with-reality/" title="Read more" >...</a>

TAVI en insuficiencia aórtica pura

TAVR Offers Better Quality of Life to Low Risk Patients

Courtesy of Dr. Carlos Fava. As we all know, TAVR is gaining ground fast in the lower risk patient population, but in addition to analyzing the most important events, researchers are increasingly looking at health status, not only at hospital level, but also after one year.   This study looked into PARTNER 3 patient health status<a href="https://solaci.org/en/2019/10/16/tavr-offers-better-quality-of-life-to-low-risk-patients/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | FORZA: OCT vs FFR to Define Intermediate Lesions: Anatomy or Function?

Courtesy of SBHCI.&nbsp; Both fractional flow reserve (FFR) and optimal coherence tomography (OCT) can be useful to help define intermediate coronary lesions and optimize PCI outcomes. The FORZA study presented at San Francisco TCT 2019 scientific sessions simultaneously published in JACC randomized patients with intermediate lesions 1:1 to FFR vs OCT. For the FFR arm,<a href="https://solaci.org/en/2019/10/01/tct-2019-forza-oct-vs-ffr-to-define-intermediate-lesions-anatomy-or-function/" title="Read more" >...</a>

TAVI en bajo riesgo con “cero” mortalidad y “cero” stroke

Very Encouraging Results for TAVR in Low-Risk Patients

Courtesy of Dr. Carlos Fava. About 12% of patients &gt;75 years old have aortic stenosis. In 3%-4% of them, such disease is severe. Transcatheter aortic valve replacement (TAVR) has already proven to be beneficial for extreme-, high-, and intermediate-risk patients. Regarding low-risk patients, we currently have different analyses; two of them are randomized and their results are<a href="https://solaci.org/en/2019/09/30/very-encouraging-results-for-tavr-in-low-risk-patients/" title="Read more" >...</a>

Top